Accomplished:

• Phase I (late) – USFDA submission
     NCE for Type II diabetes patients conducted in-house
  
  
• Phase II – USFDA submission
     NDDS formulation for patients infested with head Lice conducted in-house
  
  
• Phase II-A – Australian TGA submission
     NCE for patients infested with head Lice conducted in-house
  
  
• Phase I – DCGI and USFDA submission
     NDDS formulation for breast cancer patients conducted at 5 sites (hospitals)
  
  
• Phase III – USFDA submission
     Dermatology (patients with Tenia Pedis)